Kurian A W, Gong G D, Chun N M, Mills M A, Staton A D, Kingham K E, Crawford B B, Lee R, Chan S, Donlon S S, Ridge Y, Panabaker K, West D W, Whittemore A S, Ford J M. J. Clin. Oncol., 2008, 26: 4752—4758
[2]
Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans D G. J. Intern. Med., 2012, 271: 321—330
[3]
Gail M H, Brinton L A, Byar D P, Corle D K, Green S B, Schairer C, Mulvihill J J. J. Natl. Cancer Inst., 1989, 81: 1879—1886
[4]
Costantino J P, Gail M H, Pee D, Anderson S, Redmond C K, Benichou J, Wieand H S. J. Natl. Cancer Inst., 1999, 91: 1541—1548
[5]
NCI Breast Cancer Risk Assessment Tool. 2011, (2012-05-16).[2013-03-19]. http://www.cancer.gov/bcrisktool/
[6]
Gail M H. J. Natl. Cancer Inst., 2008, 100: 1037—1041
[7]
Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson H S, Diver W R, Thun M J, Cox D G, Hankinson S E, Kraft P, Rosner B, Berg C D, Brinton L A, Lissowska J, Sherman M E, Chlebowski R, Kooperberg C, Jackson R D, Buckman D W, Hui P, Pfeiffer R, Jacobs K B, Thomas G D, Hoover R N, Gail M H, Chanock S J, Hunter D J. N. Engl. J. Med., 2010, 362: 986—993
[8]
Nayfield S G, Karp J E, Ford L G, Dorr F A, Kramer B S. J. Natl. Cancer Inst., 1991, 83: 1450—1459
[9]
Early Breast Cancer Trialists' Collaborative Group. Lancet, 1998, 351: 1451—1467.
[10]
Early Breast Cancer Trialists' Collaborative Group. Lancet, 2005, 365: 1687—1717
[11]
Fisher B, Costantino J, Redmond C, et al. N. Engl. J. Med., 1989, 320: 479—484
[12]
Fisher B, Costantino J P, Wickerham D L, et al. J. Natl. Cancer Inst., 1998, 90: 1371—1388
[13]
Fisher B, Costantino J P, Wickerham D L, et al. J. Natl. Cancer Inst., 2005, 97: 1652—1662
[14]
Cuzick J, Powles T, Veronesi U, et al. Lancet, 2003, 361: 296—300
[15]
Ettinger B, Black D M, Mitlak B H, et al. JAMA, 1999, 282: 637—645
[16]
Cummings S R, Eckert S, Krueger K A, et al. JAMA, 1999, 281: 2189—2197
[17]
Vogel V G, Costantino J P, Wickerham D L, et al. JAMA, 2006, 295: 2727—2741
[18]
Vogel V G, Costantino J P, Wickerham D L, et al. Cancer Prev. Res. (Phila), 2010, 3: 696—706
[19]
LaCroix A Z, Powles T, Osborne C K, Wolter K, Thompson J R, Thompson D D, Allred D C, Armstrong R, Cummings S R, Eastell R, Ensrud K E, Goss P, Lee A,Neven P, Reid D M, Curto M, Vukicevic S. PEARL Investigators. J. Natl. Cancer Inst., 2010, 102: 1706—1715
[20]
Cummings S R, McClung M, Reginster J Y, Cox D, Mitlak B, Stock J, Amewou-Atisso M, Powles T, Miller P, Zanchetta J, Christiansen C. J. Bone Miner. Res., 2011, 26: 397—404
[21]
Coombes R C, Hall E, Gibson L J, Paridaens R, Jassem J, Delozier T, Jones S E, Alvarez I, Bertelli G, Ortmann O, Coates A S, Bajetta E, Dodwell D, Coleman R E, Fallowfield L J, Mickiewicz E, Andersen J, L？nning P E, Cocconi G, Stewart A, Stuart N, Snowdon C F, Carpentieri M, Massimini G, Bliss J M, vande Velde C. Intergroup Exemestane Study. N. Engl. J. Med., 2004, 350: 1081—1092
Richardson H, Johnston D, Pater J, Goss P. Curr. Oncol., 2007, 14: 89—96
[24]
Khuder S A, Mutgi A B. Br. J. Cancer, 2001, 84: 1188—1192
[25]
Hwang D, Scollard D, Byrne J, Levine E. J. Natl. Cancer Inst., 1998, 90: 455—460
[26]
Bresalier R S, Sandler R S, Quan H, et al. N. Engl. J. Med., 2005, 352: 1092—1102
[27]
Solomon S D, McMurray J J, Pfeffer M A, et al. N. Engl. J. Med., 2005, 352: 1071—1080
[28]
Goss P E, Ingle J N, Ales-Martinez J E, et al. N. Engl. J. Med., 2011, 364: 2381—2391
[29]
Decensi A, Dunn B K, Puntoni M, Gennari A, Ford L G. Cancer Discovery, 2012, 2: 25—40
[30]
Baum M, Budzar A U, Cuzick J, Forbes J, Houghton J H, Klijn J G, Sahmoud T. ATAC Trialists' Group. Lancet, 2002, 359: 2131—2139
[31]
Cuzick J, Sestak I, Baum M, et al. Lancet Oncol., 2010, 11: 1135—1141
[32]
Sestak I, Cuzick J, Sapunar F, et al. Lancet Oncol., 2008, 9: 866—872
[33]
Cuzick J. Recent Results Cancer Res., 2003, 163: 96—103; discussion 264—266
[34]
International Breast Cancer Intervention Study II. 2012,[2013-03-21]. http://www.ibis-trials.org/
[35]
International Breast Cancer Intervention Study-II. Accrual numbers., 2012. [2013-04-03]. http://www.ibis-trials.org/news/viewStory.php?storyId=186
[36]
Davies C, Pan H, Godwin J, et al. Lancet, 2013, 381(9869): 805—816
[37]
Lazzeroni M, Serrano D, Dunn BK, et al. Breast Cancer Res., 2012,14:214
[38]
Heckman-Stoddard B M, Lee O, Lazzeroni M, Khan S, DeCensi A, Dunn B K. Innovative Approaches to Tamoxifen Administration for Breast Cancer Prevention. In: Tamoxifen Concepts and Cancer: New Paradigms: Nova ScienceHauppauge. (Mello RAd, Ed.), NY: Publishers, 2013. in press.
[39]
Decensi A, Bonanni B, Guerrieri-Gonzaga A, et al. J. Natl. Cancer Inst., 1998, 90: 1461—1467
[40]
Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. J. Clin. Oncol., 1999, 17: 2633—2638
[41]
Decensi A, Robertson C, Viale G, et al. J. Natl. Cancer Inst., 2003, 95: 779—790
[42]
Kisanga E R, Gjerde J, Guerrieri-Gonzaga A, et al. Clin. Cancer Res., 2004, 10: 2336—2343
[43]
Regan M M, Neven P, Giobbie-Hurder A, et al. Lancet Oncol., 2011, 12: 1101—1108
[44]
Ferlay J, Shin H R, Bray F, Forman D, Mathers C, Parkin D M. Int. J. Cancer., 2010, 127: 2893—2917
[45]
Cancer Research U K. Cancer Stats.Breast Cancer 2011.[2013-03-18]. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/#Mortality
[46]
Siegel R, Naishadham D, Jemal A. CA Cancer J. Clin., 2013, 63:11—30
[47]
Nelson H D, Huffman L H, Fu R, Harris E L. Ann. Intern. Med., 2005, 143: 362—379
[48]
Boughey J C, Hartmann L C, Anderson S S, Degnim A C, Vierkant R A, Reynolds C A, Frost M H, Pankratz V S. J. Clin. Oncol., 2010, 28: 3591—3596
[49]
Baker L H. CA Cancer J. Clin., 1982, 32: 194—225
[50]
Arun B, Dunn B K, Ford L G, Ryan A. Semin. Oncol., 2010, 37: 367—383
[51]
Jordan V C, Ed. Tamoxifen. A Guide for Clinicians and Patients. Huntington, NY: PRR, Inc., 1996
Cuzick J, Forbes J F, Sestak I, et al. J. Natl. Cancer Inst., 2007, 99: 272—282
[59]
Cuzick J. Cancer Prev. Res. (Phila), 2010, 3: 689—691
[60]
Cummings S R, Ensrud K, Delmas P D, LaCroix A Z, Vukicevic S, Reid D M, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong R A, Thompson D D, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R. PEARL Study Investigators. N. Engl. J. Med., 2010, 362: 686—696
[61]
Baum M, Buzdar A, Cuzick J, et al. Cancer, 2003, 98: 1802—1810
[62]
Howell A, Cuzick J, Baum M, et al. Lancet, 2005, 365: 60—62
[63]
Forbes J F, Cuzick J, Buzdar A, Howell A, Tobias J S, Baum M. Lancet Oncol., 2008, 9: 45—53
[64]
Cuzick J. J. Clin. Oncol., 2005, 23: 1636—1643
[65]
Cuzick J. Expert Rev. Anticancer Ther., 2008, 8: 1377—1385
[66]
Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. J. Clin. Oncol., 2009, 27: 3749—3756
[67]
Waters E A, Cronin K A, Graubard B I, Han P K, Freedman A N. Cancer Epidemiol Biomarkers Prev., 2010, 19: 443—446
[68]
Tchou J, Hou N, Rademaker A, Jordan V C, Morrow M. Cancer, 2004, 100: 1800—1806
[69]
Decensi A, Puntoni M, Goodwin P, et al. Cancer Prev. Res. (Phila), 2010, 3: 1451—1461
[70]
Bonanni B, Puntoni M, Cazzaniga M, et al. J. Clin. Oncol., 2012, 30(21): 2593—2600
[71]
Szabo E. Semin. Oncol., 2010, 37: 359—366
[72]
Goss P E, Ingle J N, Martino S, et al. N. Engl. J. Med., 2003, 349: 1793—1802
[73]
Thurlimann B, Keshaviah A, Coates AS, et al. N. Engl. J. Med., 2005, 353: 2747—2757
[74]
Coates A S, Keshaviah A, Thurlimann B, et al. J. Clin. Oncol., 2007, 25: 486—492
[75]
Veronesi U, Maisonneuve P, Rotmensz N, et al. J. Natl. Cancer Inst., 2007, 99: 727—737otmensz N, et al. J. Natl. Cancer Inst., 2007, 99:727-737
